Science has begun to confirm what many psychedelic explorers know from personal experience: 5-MeO-DMT can bring relief from mental and emotional distress. For instance, participants in a study from 2019 reported “sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms” after a single inhalation of this stunningly potent compound.
5-MeO-DMT may now be on its way to becoming a legally sanctioned psychiatric medicine for mental health. The British group Beckley Psytech is readying the first clinical trial of intranasal 5-MeO for the treatment of neuropsychiatric disorders like addiction and depression.
In launching this project, Beckley is teaming up with the American organization Fluence to create a training program for psychedelic therapists. Trainees will be taught to help prepare patients for the administration of the 5-MeO-DMT, to assist during the 5-MeO experience itself, and to offer support during the integration period that follows.
Fluence cofounder Dr. Elizabeth Nielsen told Forbes that incorporating 5-MeO into mental health work “could be a new paradigm” for the therapists participating in this project.
“The very idea that they’re using something that they may not have considered medicinal or therapeutic as part of psychotherapy, and they’re being asked to see someone through that experience, that’s new for a lot of people,” she noted.